Cerebrospinal fluid purification system
The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.
1. A method for ameliorating a symptom of multiple sclerosis in a patient, said method comprising:
selecting a patient having a symptom of multiple sclerosis;
removing cerebrospinal fluid from a first location in a lumbar cerebrospinal fluid space of the patient;
removing a causative agent from the removed cerebrospinal fluid, thereby conditioning the cerebrospinal fluid; and
returning the conditioned cerebrospinal fluid to the patient at a second location in a cervical cerebrospinal fluid space, a thoracic cerebrospinal fluid space, or a ventricle of the patient, wherein the cerebrospinal fluid is returned to the patient at substantially the same flow rate at which it is removed;
wherein the removing and returning steps are performed concurrently using one or more catheters, each catheter comprising one or more lumens.
2. A method as in claim 1 , wherein the one or more catheters comprises a single catheter comprising a first lumen with a first proximal port at the first location and a second lumen having a second distal port at the second location during at least a portion of a conditioning treatment.
3. A method as in claim 1 , wherein the one or more catheters comprises a first catheter inserted at the first location and a second catheter inserted at the second location during at least a portion of a conditioning treatment.
4. A method as in claim 3 , wherein the first catheter and the second catheter each comprise a single lumen.
5. A method as in claim 1 , wherein the step of removing includes removing at least one or more of T cells, B cells, anti-myelin antibodies and inflammatory mediators selected from the group consisting of TNF-α, IL-2, IL-6, and interferon-γ.
6. A method as in claim 1 , wherein the flow rate is in a range from 0.04 ml/min to 30 ml/min.
7. A method as in claim 1 , wherein a volume of cerebrospinal fluid removed from the patient at any given time never exceeds 40 ml.
8. A method as in claim 1 , wherein the second location is in the cervical cerebrospinal fluid space.
9. A method as in claim 1 , wherein the second location is in the ventricle of a brain.
10. A method as in claim 1 , wherein the second location is in a thoracic cerebrospinal fluid space.
11. A method as in claim 1 , wherein flow directions of removing and returning cerebrospinal fluid are periodically reversed so that CSF is returned to the first location and removed from the second location during a portion of the treatment.
12. A method as in claim 1 , further comprising mixing the conditioned cerebrospinal fluid with endogenous cerebrospinal fluid as the conditioned cerebrospinal fluid is returned to the cerebrospinal fluid space.
13. A method as in claim 12 , wherein mixing comprises inducing a turbulent flow as the conditioned cerebrospinal fluid is returned.
14. A method as in claim 1 , wherein the conditioning comprises one or more separation processes selected from the group consisting of biospecific affinity, immunoaffinity, cationic exchange, anionic exchange, hydrophobicity, and size exclusion.
15. A method as in claim 1 , wherein the causative agent is removed from the CSF using one or more of an immunoaffinity column, a size exclusion column, an anionic exchange column, a cationinc exchange column, a Protein A column, or a Protein G column.
16. A method as in claim 1 , wherein the conditioning step is performed externally to the patient's body.
17. A method for ameliorating a symptom of Guillain Barre Syndrome in a patient, said method comprising:
selecting a patient having a symptom of Guillain Barre Syndrome;
removing cerebrospinal fluid from a first location in a lumbar cerebrospinal fluid space of the patient;
removing a causative agent from the removed cerebrospinal fluid, thereby conditioning the cerebrospinal fluid; and
returning the conditioned cerebrospinal fluid to the patient at a second location in a cervical cerebrospinal fluid space, a thoracic cerebrospinal fluid space, or a ventricle of the patient, wherein the cerebrospinal fluid is returned to the patient at substantially the same flow rate at which it is removed;
wherein the removing and returning steps are performed concurrently using one or more catheters, each catheter comprising one or more lumens.
18. A method as in claim 17 , wherein the step of removing includes removing at least one or more of cells and inflammatory mediators selected from the group consisting of C5a, TNF-α, IL-2, IL-6, and interferon-γ, IgG an endotoxins.
19. A method as in claim 17 , wherein the one or more catheters comprises a single catheter comprising a first lumen with a first proximal port at the first location and a second lumen having a second distal port at the second location during at least a portion of a conditioning treatment.
20. A method as in claim 17 , wherein the one or more catheters comprises a first catheter inserted at the first location and a second catheter inserted at the second location during at least a portion of a conditioning treatment.